Two phase two clinical trials testing the ETAR antagonists atrasentan and zibotentan with Pegylated liposomal doxorubicin (PLD) and carboplatin or paclitaxel as second-line therapy for advanced and refractory ovarian cancer failed to demonstrate a clear benefit for patients treated with an ETAR antagonist [109,115]. Here, EDNRA is linked to ovarian carcinoma.